← Back to Clinical Trials
Recruiting NCT07562997

NCT07562997 Sodium and Milk Fortification Evaluation of Body Composition Among Very Preterm Infants

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07562997
Status Recruiting
Phase
Sponsor University of Washington
Condition Very Preterm and Extremely Preterm Birth
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2026-05-18
Primary Completion 2029-06-01

Eligibility & Interventions

Sex All sexes
Min Age 0 Days
Max Age 14 Days
Study Type INTERVENTIONAL
Interventions
Urine sodium testingSerum sodium testingMilk fortification

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2026-05-18 with a primary completion date of 2029-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of the trial is to learn if targeted sodium supplementation (including blood and urine sodium testing) versus standard milk fortification (including blood sodium testing) improves growth and body composition in very preterm infants?

Eligibility Criteria

Inclusion Criteria: * Admitted to the University of Washington, Oregon Health and Sciences, or University of Cincinnati NICU at 14 days of age * Born between 24w0days and 31w6d * Achieved full enteral feeding Exclusion Criteria: * Congenital or chromosomal anomalies affecting growth * Acute renal insufficiency (KDIGO stage 1 or higher) * Necrotizing enterocolitis (modified Bell's stage IIA or higher) * Anticipated NICU stay less than 30 days * Enrollment in a concurrent interventional study that may confound study outcomes

Contact & Investigator

Central Contact

John Feltner, MS

✉ jfeltner@uw.edu

📞 (206) 543-3200

Principal Investigator

Katie Strobel, MD, MSCR

PRINCIPAL INVESTIGATOR

University of Washington

Frequently Asked Questions

Who can join the NCT07562997 clinical trial?

This trial is open to participants of all sexes, aged 0 Days or older, up to 14 Days, studying Very Preterm and Extremely Preterm Birth. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07562997 currently recruiting?

Yes, NCT07562997 is actively recruiting participants. Contact the research team at jfeltner@uw.edu for enrollment information.

Where is the NCT07562997 trial being conducted?

This trial is being conducted at Cincinnati, United States, Portland, United States, Seattle, United States.

Who is sponsoring the NCT07562997 clinical trial?

NCT07562997 is sponsored by University of Washington. The principal investigator is Katie Strobel, MD, MSCR at University of Washington. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology